Trial Profile

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 26 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenalidomide (Primary) ; Ruxolitinib (Primary) ; Methylprednisolone
Indications Multiple myeloma; Plasmacytoma
Focus Adverse reactions
Acronyms I-RUX

Most Recent Events

21 Dec 2023 According to American Oncology Network media release, data from the study were presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition.
30 Oct 2023 Planned primary completion date changed from 1 Sep 2022 to 1 Sep 2024.
20 Dec 2022 According to an ONCOtherapeutics media release, results from this trial were published online in the British Journal of Haematology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com